Clinical Trial

Molecular and Cellular Characterization of MALT Lymphoma

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is an slow growing malignancy characterized by marked biological and clinical differences across different anatomical sites. Using participants' samples and clinical information, this observational and non-interventional research aims to generate a comprehensive molecular and cellular atlas of MALT lymphoma. The results will enable the identification of biologically meaningful tumor subtypes, microenvironmental niches, and candidate biomarkers with potential relevance for the diagnosis, prognosis, and therapy of MALT lymphoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-22; most recent amendment 2026-06-18.
Trial Details
NCT Number NCT07376330
Lead Sponsor International Extranodal Lymphoma Study Group (IELSG)
Conditions MALT Lymphoma
Enrollment 400 participants
Start Date 2026-09
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-22